Paul DiSilvestro

Providence College — United States

Medicine · Health Sciences

47h-index15.2kcitations273works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(150), Endometrial and Cervical Cancer Treatments(83), PARP inhibition in cancer therapy(43), BRCA gene mutations in cancer(29), Cervical Cancer and HPV Research(27)

Publications270 total

PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240
International Journal of Gynecological Cancer·2025
Abstract B048: Clinically relevant implications of human epidermal growth factor receptor 2 expression and associated antibody-drug conjugate targeting in high grade serous ovarian cancer
Cancer Research·2025
Abstract A045: Amphiregulin neutralization reduces tumor burden and combats immunosuppression within the ovarian tumor microenvironment
Cancer Research·2025
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation
Gynecologic Oncology·2025· 3 cited
1070P Quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from the PRIMA/ENGOT-OV26/GOG-3012 final analysis
Annals of Oncology·2025
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249
Gynecologic Oncology·2025
1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer
Annals of Oncology·2025
Combinatorial platinum-taxane based chemotherapy and amphiregulin blockade significantly promotes tumor regression in a high-grade serous ovarian cancer immunocompetent murine model
Gynecologic Oncology·2025
The effect of intrawound vancomycin powder on surgical site infection in inguinal lymph node dissection: a randomized controlled trial pilot study
Gynecologic Oncology Reports·2025Open Access
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
Gynecologic Oncology·2025· 7 cited
Distribution and concordance of HER2 scores in endometrial and ovarian cancer
Gynecologic Oncology·2025· 2 cited
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study
Gynecologic Oncology·2025· 8 citedOpen Access
Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation
International Journal of Gynecological Cancer·2025· 1 cited
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Journal of Clinical Oncology·2024· 6 cited
LB002/#1594  Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: exploratory analyses of biomarker/histological heterogeneity and efficacy in the DUO-E mismatch repair proficient subpopulation
2024· 5 cited
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology·2024· 117 citedOpen Access
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
Journal of Clinical Oncology·2024· 15 citedOpen Access
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
Gynecologic Oncology·2024· 14 citedOpen Access
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology·2024· 12 citedOpen Access
SO018/#362  Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) outcomes: ancillary analysis of GOG-0258
2023· 5 citedOpen Access
page 1 of 14Next →

Frequent Co-authors

Kathleen N. Moore(13), Carol Aghajanian(12), Robert S. Mannel(12), Krishnansu S. Tewari(12), David S. Miller(10), David E. Cohn(9), Byoung‐Gie Kim(8), Ana Oaknin(8), Michael Friedländer(8), Amit M. Oza(8), Antonio González-Martı́n(8), William H. Bradley(8), Joan L. Walker(8), David M. O’Malley(8), Helen Huang(8), Virginia L. Filiaci(8), Matthew A. Powell(8), Nicoletta Colombo(7), Giovanni Scambia(7), Alla Lisyanskaya(7)